English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/116890
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Tyrosine aminotransferase from Leishmania infantum: A new drug target candidate

AuthorsMoreno-Izquierdo, Miguel A. ; Alonso, Ana ; Alcolea, Pedro J. ; García de Lacoba, Mario ; Larraga, Vicente
KeywordsLeishmania infantum
Tyrosine aminotransferase
Issue DateDec-2014
CitationInternational Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 347–354
AbstractLeishmania infantum is the etiological agent of zoonotic visceral leishmaniasis in the Mediterranean basin. The disease is fatal without treatment, which has been based on antimonial pentavalents for more than 60 years. Due to resistances, relapses and toxicity to current treatment, the development of new drugs is required. The structure of the L. infantum tyrosine aminotransferase (LiTAT) has been recently solved showing important differences with the mammalian orthologue. The characterization of LiTAT is reported herein. This enzyme is cytoplasmic and is over-expressed in the more infective stages and nitric oxide resistant parasites. Unlike the mammalian TAT, LiTAT is able to use ketomethiobutyrate as co-substrate. The pharmacophore model of LiTAT with this specific co-substrate is described herein. This may allow the identification of new inhibitors present in the databases. All the data obtained support that LiTAT is a good target candidate for the development of new anti-leishmanial drugs.
Description8 p.-5 fig. Moreno, Miguel A. et alt.
Publisher version (URL)http://dx.doi.org/ 10.1016/j.ijpddr.2014.06.001
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
Int. J. Parasitology_Larraga V._2014.pdf1,69 MBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.